British scientists seek to reuse existing antiviral drugs for COVID By Reuters

© Reuters. FILE PHOTO: A 3D printed model of the coronavirus is seen in front of the words coronavirus disease (Covid-19) displayed in this illustration taken March 25, 2020. REUTERS/Dado Ruvic/Illustration

(Reuters) – British researchers want to reuse existing antiviral therapies to treat COVID-19, the University of Oxford said on Friday, in a bid to avoid lengthy development processes with readily available drugs.

Scientists will initially screen 138 drugs with known antiviral activity against the SARS-CoV-2 virus that causes COVID to study and identify potent combinations, the university said in a statement news/2022-02-04-the-research-collaboration-launched-focus-repurposing-existing-anti-viral-therapies on Friday.

The rapid spread of Omicron across the world has also forced researchers to find options that work against the variant. Britain currently has the seventh highest number of COVID cases in the world, according to Reuters.

The most effective combinations discovered through the project will be presented to UK authorities, including the Antiviral Task Force and UK-CTAP, so they can be added to clinical trials, Oxford said.

“There are multiple benefits to discovering new treatments in this way,” said Ultan Power, one of the project’s lead researchers.

“They have undergone all the necessary checks, so we know they are safe and readily available, they can be self-administered and used at home, helping to reduce the burden on the healthcare system.”

The 1.6 million pound ($2.2 million) project is being led by Queen’s University Belfast, with experts from Queen’s, the University of Liverpool and Oxford. It is funded by the UK Medical Research Council.

($1 = 0.7369 pounds)

Warning: Merged media would like to remind you that the data contained in this site is not necessarily real time or exact. All prices for CFDs (stocks, indices, futures) and Forex are not provided by exchanges but rather by market makers, and therefore prices may not be accurate and may differ from the actual market price, which which means that the prices are indicative and not suitable for commercial purposes. Therefore, Fusion Media assumes no responsibility for any business losses you may incur due to the use of this data.

Merged media or anyone involved with Fusion Media will accept no liability for any loss or damage resulting from reliance on the information, including data, quotes, charts and buy/sell signals contained in this website . Please be fully informed of the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investment possible.

Comments are closed.